Pharmafile Logo
Pharmafocus logo
Advanced Search

sarilumab

Showing 11 posts of 11 posts found.

Sanofi’s arthritis treatment Kevzara secures NICE recommendation

September 25, 2017
Sales and Marketing Kevzara, NICE, Sanofi, pharma, pharmaceutical, rheumatoid arthritis, sarilumab

Sanofi, along with its speciality care global business unit Sanofi Genzyme, are celebrating the news that NICE has passed its …

News

Sanofi and Regeneron score FDA approval for arthritis

May 23, 2017
Manufacturing and Production, Sales and Marketing FDA, Kevzara, arthritis, sarilumab

The FDA has awarded Sanofi and Regeneron’s Kevzara (sarilumab) approval for the treatment of moderate to severely active rheumatoid arthritis …

News
ema_building_face_web

EU recommendation for Sanofi and Regeneron’s arthritis treatment

April 24, 2017
Sales and Marketing Kevzara, NICE, sarilumab

Sanofi and Regeneron are celebrating the news that their treatment Kevzara (sarilumab) has received a positive opinion from the EMA’s …

News

Sanofi & Regeneron’s arthritis drug scores first approval following FDA rejection

February 1, 2017
Research and Development, Sales and Marketing Actemra, Humira, Kevzara, Regeneron, Roche, Sanofi, sarilumab

Kevzara (sarilumab), a interleukin-6 (IL06) receptor antibody developed by Sanofi and Regeneron and the first real competitor to Roche’s Actemra …

News

FDA rejects Sarilumab due to production facility issues

October 31, 2016
Manufacturing and Production, Sales and Marketing FDA, Regeneron, Sanofi, sarilumab

The US Food and Drugs administration has decided to reject the application for Sarilumab, Regeneron and Sanofi’s rheumatoid arthritis treatment, …

News
gsk_hq_close

GSK and J&J file rheumatoid arthritis treatment sirukumab in EU

September 13, 2016
Manufacturing and Production, Sales and Marketing GSK, GlaxoSmithKline, Johnson & Johnson, rheumatoid arthritis, sarilumab, sirukumab

GlaxoSmithKline and partner Johnson & Johnson’s Janssen Biologics unit have filed for approval of rheumatoid arthritis (RA) treatment sirukumab in …

News
4420456374_64a3d7e6aa

Top ten stories in the pharmaceutical industry this week

August 5, 2016
Medical Communications, Research and Development Actavis, Bioelectronics, CDF, Celgne, EMA, GSK, GlaxoSmithKline, Innovate UK, Medivation, NICE, Novartis, Roche, Sanofi, Teva, appointments, apremilast, biog, breast cancer, brexit, google, pharmaceutical industry, rheumatoid arthritis, sarilumab, top ten

It’s Friday, and we’ve seen some big developments in the industry’s headlines throughout the week, from news of Glaxo-Smith-Kilne’s new …

News
a_scientist_at_work_at_sanofis_immunology_laboratory_in_thailand

EMA accepts MMA for rheumatoid arthritis treatment Sarilumab

August 1, 2016
Research and Development, Sales and Marketing EMA, MAA, Regeneron, Sanofi, sarilumab

Sanofi and Regeneron Pharmaceuticals have announced that the European Medicines Agency (EMA) has accepted the Marketing Authorisation Application (MAA) for …

News
FDA sign

FDA review for Sanofi and Regeneron’s biologic arthritis drug

January 8, 2016
Medical Communications, Sales and Marketing FDA, Regeneron, Sanofi, biologics, rheumatoid arthritis, sarilumab

The FDA has accepted for review a Biologics License Application (BLA) from Sanofi and Regeneron for the rheumatoid arthritis treatment …

News
Sanofi image

Sanofi’s rheumatoid arthritis biologic performs

May 22, 2015
Sales and Marketing Sanofi, rheumatoid arthritis, sarilumab

French pharma giant Sanofi plans to submit its new rheumatoid arthritis biologic for regulatory approval in the US after it …

News

Sanofi eyes phase III move for sarilumab in rheumatoid arthritis

July 13, 2011
Research and Development Regeneron, Sanofi, ankylosing spondylitis, research and development news, rheumatoid arthritis, sarilumab

Sanofi is poised to move sarilumab into phase III trials for rheumatoid arthritis after the monoclonal antibody showed positive results …

News

Latest content

Tolremo doses first patient in phase 1 trial for drug to combat transcriptional cancer drug resistance

November 29, 2023

FDA grants breakthrough device designation to Inflammatix’s TriVerity Acute Infection and Sepsis Test System

November 29, 2023

FDA accepts new drug application for Orexo’s opioid overdose medication

November 28, 2023

Arcturus Therapeutics gains FDA ODD for cystic fibrosis treatment

November 28, 2023

Sanofi and Regeneron share results from phase 3 trial for Dupixent as COPD treatment

November 27, 2023